Targeting NF-κB in aggressive thyroid carcinomas represents a novel and hopeful therapeutic opportunity, but, unfortunately, it is difficult to achieve without interfering with NF-κB physiologic functions. Here, NFKB1 is linked to thyroid gland carcinoma.